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OBJECTIVE—Osteopontin (OPN) plays an important role in
the development of insulin resistance and liver complications in
dietary murine models. We aimed to determine the expression
pattern of OPN and its receptor CD44 in obese patients and mice
according to insulin resistance and liver steatosis.
RESEARCH DESIGN AND METHODS—OPN and CD44 ex-
pressions were studied in 52 morbidly obese patients and in
mice. Cellular studies were performed in HepG2 cells.
RESULTS—Hepatic OPN and CD44 expressions were strongly
correlated with liver steatosis and insulin resistance in obese
patients and mice. This increased OPN expression could be due
to the accumulation of triglycerides, since fat loading in HepG2
promotes OPN expression. In contrast, OPN expression in adi-
pose tissue (AT) was enhanced independently of insulin resis-
tance and hepatic steatosis in obese patients. The elevated OPN
expression in AT was paralleled with the AT macrophage inﬁl-
tration, and both phenomena were reversed after weight loss.
The circulating OPN level was slightly elevated in obese patients
and was not related to liver steatosis. Further, AT did not appear
to secrete OPN. In contrast, bariatric surgery–induced weight
loss induced a strong increase in circulating OPN.
CONCLUSIONS—The modestly elevated circulating OPN levels
in morbidly obese patients were not related to liver steatosis and
did not appear to result from adipose tissue secretion. In
subcutaneous AT, expression of OPN was directly related to
macrophage accumulation independently from liver complica-
tions. In contrast, hepatic OPN and CD44 expressions were
related to insulin resistance and steatosis, suggesting their local
implication in the progression of liver injury. Diabetes 58:
125–133, 2009
T
he incidence of overweight and obesity is rapidly
increasing in many Western countries. This epi-
demic of obesity is associated with the develop-
ment of type 2 diabetes, hypertension, and
nonalcoholic fatty liver disease (NAFLD). These often-ig-
nored hepatic abnormalities extend from simple steatosis to
steatohepatitis (nonalcoholic steato-hepatitis [NASH]) and
steatoﬁbrosis leading, in some cases, to cirrhosis and hepa-
tocellular carcinoma. NAFLD are frequently observed in the
setting of visceral obesity, insulin resistance, and metabolic
syndrome (1). Obesity is associated with a low-grade chronic
inﬂammation, as evidenced by increased systemic concentra-
tions of inﬂammatory markers and cytokines (2,3). The
accumulation of macrophages in obese adipose tissue, a key
source of inﬂammation (4,5), provides a causal link between
the development of insulin resistance and liver complications
(6). The combined elevation of plasma glucose and insulin
levels promotes de novo lipid synthesis and impairs lipid
oxidation within hepatocytes (6–8). Moreover, insulin resis-
tance of adipose tissue leads to an enhanced delivery of free
fatty acids to the liver, contributing to the excessive fatty
acids accumulation (6,8). Recently, it has been proposed that
osteopontin (OPN), a Th1 cytokine, could play an important
role in the development of insulin resistance and NAFLD in
dietary murine models (9–11).
OPN binds to multiple receptors including the integrin
receptors and CD44 (12,13). This cytokine is involved in
cell adhesion, chemo-attraction, and immunomodulation
(13–15). In particular, OPN is highly secreted by macro-
phages at inﬂammation sites where it mediates monocyte
adhesion, migration, and differentiation as well as phago-
cytosis (16–18). Recently, an elevated expression of OPN
has been detected in human and mice adipose tissue
(9,19,20). Elevated plasma levels of OPN have been asso-
ciated with human and mice obesity (9,19), and weight
loss after low-caloric diets was associated with a reduc-
tion of OPN plasma levels in obese patients (19). Further-
more, peroxisome proliferator–activated receptor (PPAR)
ligands inhibited the OPN expression in macrophages
(21,22), and treatment with bezaﬁbrate in type 2 diabetic
patients was correlated with reduced OPN levels (21).
Recently, Nomiyama et al. (9) have identiﬁed OPN as a link
between adipose tissue inﬂammation and insulin resis-
tance in a murine model of diet-induced obesity. Similarly,
OPN can also play an important role in the occurrence of
liver complications, as suggested by Sahai et al. (10) in
OPN null mice.
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ORIGINAL ARTICLE
DIABETES, VOL. 58, JANUARY 2009 125Based on the evidence that OPN can be considered as a
potential actor in obesity-induced complications in mice
(9,10), we ﬁrst analyzed the expression pattern of OPN and
its receptor CD44 in morbidly obese patients according to
steatosis and insulin resistance. In addition, OPN and
CD44 expressions were evaluated in human adipose tissue
after a surgically induced weight loss associated with a
marked reduction of inﬂammation and insulin resistance.
We then looked for a direct effect of fat loading on OPN
expression in a hepatocyte cell line.
RESEARCH DESIGN AND METHODS
Wild-type C57BL/6 male mice (7–10 weeks of age), obtained from Janvier (Le
Genest-St-Isle, France), had free access to water and were fed a standard diet
(n  8) (TD2016, Harlan) or a high-fat diet (HFD, n  10) containing 36% fat
(TD99249, Harlan) for 15 weeks. At the time of death, white epididymal
adipose tissue pads and liver samples were removed, immediately frozen in
liquid nitrogen, and stored at 80°C until used. Serum OPN levels were
determined by ELISA (R&D Systems, Lille, France).
Isolation of hepatocytes and nonparenchymal fraction from liver.
Mouse livers were perfused ﬁrst with a HEPES buffer containing 8 g/l NaCl, 33
mg/l Na2HPO4, 200 mg/l KCl, and 2.38 g/l HEPES, pH 7.65, for 2 min at 5 ml/min
and then with HEPES buffer supplemented with 1.5 g/l CaCl2 and 25 mg/l
liberase (Roche Diagnostics) for 7 min at 5 ml/min. Livers were then carefully
removed and minced, and the resultant cell suspension was then ﬁltered (100
m). Hepatocytes were collected by centrifugation for 5 min at 50g and then
on a Percoll density gradient (20 min, 500g) (Sigma). Hepatocytes were then
washed in NaCl 0.9%, isolated by centrifugation (5 min, 50g), and frozen at
80°C before RNA extraction, as described below. The nonparenchymal cells
in the supernatant of ﬁrst centrifugation were collected by centrifugation for
5 min at 450g and then incubated in NaCl 0.9% buffer supplemented with 0.02%
pronase E (Sigma) for 20 min at 37°C under gentle agitation. Finally, cells
were collected by centrifugation at 450g for 5 min and frozen at 80°C before
RNA extraction as described below.
Patient population. The patient cohort included 52 morbidly obese patients.
These patients were recruited through the Department of Digestive Surgery
and Liver Transplantation, where they underwent bariatric surgery for their
morbid obesity (Nice and Paris hospitals). Bariatric surgery was indicated for
these patients in accordance with the French Guidelines for obesity surgery.
Brieﬂy, they had a BMI 40 or 35 kg/m
2 with at least one complication.
Exclusion criteria were as follows: presence of hepatitis B or hepatitis C virus
infection, excessive alcohol consumption (20 g/day), or another cause of
chronic liver diseases (primary biliary cirrhosis, autoimmune hepatitis, Wilson
disease, genetic hemochromatosis, or biliary disease). The clinical and
biological characteristics of the study groups are described in Table 1. Before
surgery, fasting blood samples were obtained and used to measure alanine
amino transferase (ALAT), glucose, insulin, HDL cholesterol, LDL cholesterol,
triglycerides, and C-reactive protein (CRP) levels. Serum OPN levels were
determined by ELISA (R&D Systems, Lille, France). The degree of insulin
resistance was calculated by using the homeostatic model assessment–insulin
resistance (HOMA-IR) index (23). Surgical liver biopsies were obtained at the
time of bariatric surgery. Part of the biopsy was immediately frozen in liquid
nitrogen and stored at 80°C until analyzed. The other part was ﬁxed in Bouin
solution, parafﬁn-embedded, sectioned, and stained with hematoxylin-eosin-
safran and picro-sirius red. Steatosis was graded from 0–3 based on percent
of hepatocytes in the biopsy affected: 0 for none (S0, n  6); 1 for 30% (S1,
mild steatosis, n  13); 2 for 30–60% (S2, moderate steatosis, n  9); and 3 for
60% (S3, severe steatosis, n  24). Subcutaneous and visceral adipose tissue
samples were also obtained from 39 patients and frozen until analyzed. The
percentage of macrophages in subcutaneous adipose tissue of 19 patients has
been evaluated by immunohistochemical analysis as previously described
(24). In addition, abdominal subcutaneous adipose tissue was obtained from
six women before (age 40.7  3.2 years; BMI 42.7  2.0 kg/m
2) and 2 years
after (BMI 26.0  1.6 kg/m
2) weight loss following bariatric surgery (mean
weight loss 44.3  11.4 kg). Serum was obtained from 25 patients before (BMI
43.9  5.3 kg/m
2) and 1 year after (BMI 27.9  3.8 kg/m
2) weight loss following
bariatric surgery (mean weight loss 42.3  12.3 kg). The second surgery was
performed for cosmetic purpose.
Control subjects. Total RNA from six control livers was purchased from
Stratagene (La Jolla, CA) (female, 34 years old, normal adjacent tissue to
stromal sarcoma), Clontech (Mountain View, CA) (male, 51 years old, sudden
death), and Biochain (Hayward, CA) (four males: 24, 26, 28, and 30 years old,
sudden deaths). The Stratagene and Biochain companies conﬁrmed that
histological ﬁndings were completely normal with no evidence of fatty liver
disease. No clinical or biological data were available for these individuals, but
the absence of an inﬂammatory process was corroborated by low CRP mRNA
expression levels, as previously reported (3,25). Control subcutaneous adi-
pose tissue was obtained from seven lean subjects (ﬁve females and two
males; age 36.7  8.4 years; BMI 21.5  1.9 kg/m
2) undergoing lipectomy for
cosmetic purposes. Finally, serum was obtained from eight lean healthy
volunteers (six females and two males; age 31.6  2.4 years; BMI 21.2  0.3
kg/m
2) after an overnight fast. All subjects gave their informed consent to
participate in this research study according to French legislation regarding
Ethic and Human Research (Huriet-Serusclat law, DGS 2003/0395).
Arteriovenous differences across the adipose tissue. The protocol was
approved by the Oxfordshire Clinical Research Ethics Committee, and all
subjects gave written informed consent. Five overweight healthy subjects
(four men, one woman, BMI 27  1 kg/m
2) were studied after an overnight
fast. A 10 cm, a 22-gauge Hydrocath catheter (Becton Dickinson, U.K.) was
introduced over a guide wire into a superﬁcial vein on the anterior abdominal
wall and threaded toward the groin so that its tip lay just superior to the
inguinal ligament. This provided access to the venous drainage from the
subcutaneous abdominal adipose tissue, uncontaminated by muscle drainage
and with a relatively minor contribution from skin (26). A retrograde cannula
was placed in a vein draining the hand, which was warmed in a hot-air box
maintained at 60°C to obtain arterialized blood. The cannulae were kept
patent by a slow infusion of 0.9% (wt/vol) saline. After a resting period of at
least 30 min, blood samples were taken simultaneously from the arterialized
and adipose tissue venous lines.
Real-time quantitative PCR analysis. Total RNA was extracted from
human and animal tissues using the RNeasy Mini Kit (Qiagen, Contraboeuf,
France) and treated with Turbo DNA-free (Applied Biosystems, Contraboeuf,
France) following the manufacturer’s protocols. The quantity and quality of
the isolated RNA were determined using the Agilent 2100 Bioanalyser with
RNA 6000 Nano Kit (Agilent Technologies). One microgram of total RNA was
reverse-transcribed with a High-Capacity cDNA Reverse Transcription Kit
TABLE 1
Characteristics of the morbidly obese patients according to grade of hepatic steatosis
S0 S1 S2 S3
n 61 3 9 2 4
Sex (F/M) 5/1 12/1 6/3 16/8
BMI (kg/m
2) 42.1  0.6 44.7  1.5 45.0  2.0 43.8  1.1
Age (years) 41.8  4.8 40.4  2.3 43.2  4.4 39.1  1.9
ALAT (IU/l) 19.5  4.4 19.8  2.0 27.6  3.6*† 57.0  10.9*†‡
Blood glucose (mmol/l) 5.1  0.0 5.9  0.9 7.5  1.0*† 6.6  0.5*†
Insulin (mol/l) 8.0  0.9 12.7  3.9 14.4  2.6 20.9  2.7*†
HOMA-IR 1.8  0.2 3.3  1.2 5.0  1.3* 6.1  0.8*†
HDL cholesterol (mmol/l) 1.6  0.1 1.4  0.1 1.4  0.1 1.3  0.1
LDL cholesterol (mmol/l) 3.2  0.5 3.8  0.3 3.2  0.2 3.4  0.2
Triglycerides (mmol/l) 1.2  0.1 1.8  0.2 1.4  0.2 2.6  0.4*
C-reactive protein (mg/l) 8.8  3.2 13.3  1.6 9.1  1.8 8.3  1.1
Data are means  SE and were compared by using the nonparametric Kruskal-Wallis test. *P  0.05 compared with S0; †P  0.05 compared
with S1; ‡P  0.05 compared with S2.
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performed in duplicate for each sample using the ABI PRISM 7500 Fast
Real-Time PCR System and FAM dyes (Applied Biosystems, Contraboeuf,
France) as previously described (3,25). The TaqMan gene expression as-
says were purchased from Applied Biosystems: OPN (Hs00167093_m1,
Mm00436767_m1); CD44 (Hs00153304_m1; Mm01277163_m1), CD11b
(Hs00355885_m1), CD68 (Hs00154355_m1), TNF (Hs00174128_m1), F4/80
(Mm00802530_m1), RPLP0 (large P0 subunit of the acidic ribosomal phospho-
protein, Hs99999902_m1), and 36B4, (Mm99999223_gH).
OPN immunoblotting. Proteins were extracted from patient frozen liver
samples using the NucleoSpin RNA/Protein kit (Macherey-Nagel, France)
according to the manufacturer’s protocol. Proteins (50 g) were separated by
SDS-PAGE using a 10% resolving gel. The Western blotting was performed as
previously described (27). The proteins were probed with anti-OPN (AKm2A1)
or anti-GAPDH (FL-335) antibodies (Santa Cruz Biotechnology, Santa Cruz,
CA) at 1 g/ml.
Oleic acid–induced fat loading in HepG2 cells. Human HepG2 cells were
cultured in DMEM supplemented with 10% fetal bovine serum under 5% CO2
at 37°C. At 75% conﬂuence, medium was exchanged for new medium with or
without 1 mmol/l oleic acid for 24 h (28). Hepatic triglycerides were extracted
with a methanol-chloroform mixture and measured using an enzymatic assay
(Diagnostic Systems International, Germany). Results were normalized to
protein content measured by BCA assay (Pierce, Perbio Science France,
Brebie ´res, France).
Statistical analysis. Results are expressed as means  SE. Statistical
signiﬁcance of differential gene expression between two study groups was
determined using the nonparametric Kruskal-Wallis with the Ct of each
group. Correlations were analyzed using Spearman’s rank correlation test.
Other data were statistically analyzed using the Student’s t test. P  0.05 was
considered as signiﬁcant.
RESULTS
OPN and CD44 gene expressions in livers from mor-
bidly obese patients. We studied the OPN and CD44
gene expression in the whole cohort of 52 morbidly obese
patients included in the study (Table 1), who were strati-
ﬁed according to the degree of the fat inﬁltration in liver.
We report for the ﬁrst time that the hepatic OPN and CD44
gene expression was signiﬁcantly correlated with the
grade of hepatic steatosis (from S0 to S3) (Fig. 1A).
Noteworthy, when compared with control values, OPN
and CD44 gene expressions were markedly increased in S3
patients (9.2  2.6-fold and 3.5  0.3-fold, respectively;
P  0.05), whereas CD44 expression was barely increased
in S0 patients (Fig. 1A). Furthermore, the hepatic OPN and
CD44 gene expression was also signiﬁcantly correlated
with plasma ALAT levels (rs  0.567, P  0.001, and rs 
0.549, P  0.001, respectively) and the insulin resistance as
evaluated by the HOMA-IR (rs  0.474, P  0.001, and rs 
0.587, P  0.001, respectively) (data not illustrated).
Finally, the OPN protein expression was evaluated by
Western blot in total liver lysates obtained from three
morbidly obese patients without steatosis (S0) and six
with severe steatosis (S3). In accordance with mRNA
expression level, the OPN protein level was barely detect-
able in livers from S0 patients, whereas strong signals
A
Total lysates
α α-OPN
α α-GAPDH
IB :
S0 S3
C B
-9
-8
-7
-6
-5
-4
-3
-2
-1
-13
rs=0.565
P=0.003
n=25
-12 -11 -10 -9 -8 -7 -6
TNFα mRNA level (-∆Ct)
O
P
N
 
m
R
N
A
 
l
e
v
e
l
 
(
-
∆
C
t
)
0
2
4
6
8
10
12
14
S0 S1 S2 S3
rs=0.567
P<0.001
n=58
O
P
N
 
m
R
N
A
 
l
e
v
e
l
(
r
e
l
a
t
i
v
e
 
e
x
p
r
e
s
s
i
o
n
) *#$
*
Obese
0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
4.5
S0 S1 S2 S3
Obese
C
D
4
4
 
m
R
N
A
 
l
e
v
e
l
(
r
e
l
a
t
i
v
e
 
e
x
p
r
e
s
s
i
o
n
) rs=0.667
P<0.001
n=58
*
*#$
*#
*#
FIG. 1. The hepatic OPN and CD44 expression is signiﬁcantly correlated with the grade of steatosis in morbidly obese patients. A: Hepatic OPN
and CD44 mRNA expression levels were analyzed by real-time quantitative PCR in lean patients (controls; n  6), in morbidly obese patients
without liver steatosis (S0; n  6), and in morbidly obese patients with S1 (n  13), S2 (n  9), and S3 (n  24) steatosis. The gene expression
of OPN and CD44 was normalized to the mRNA levels of RPLP0. Results are expressed relative to the expression level in controls and expressed
as means  SE. *P < 0.05 compared with controls; #P < 0.05 compared with S0; $P < 0.05 compared with S1. B: Total lysates from liver biopsies
obtained from three morbidly obese patients without steatosis (S0) and six with severe steatosis (S3) were separated by SDS-PAGE and
immunoblotted with anti-OPN or anti-GAPDH antibodies. A representative immunoblot is shown. C: Correlation between OPN and TNF- mRNA
expression levels (Ct) in lean subjects (n  5) and morbidly obese patients without (n  6) or with severe steatosis (n  14) was analyzed using
Spearman’s rank correlation test.
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DIABETES, VOL. 58, JANUARY 2009 127were observed in livers from S3 patients (Fig. 1B). Be-
cause tumor necrosis factor (TNF)- can stimulate the
OPN gene expression in hepatocytes (10), we evaluated
the TNF- gene expression of S3 patients (n  15)
compared with S0 patients (n  6) and controls (n  5).
Interestingly, the gene expression of TNF- was fourfold
increased in S3 patients compared with S0 patients (P 
0.004) (data not shown). Moreover, the OPN gene expres-
sion was positively correlated with the TNF- gene expres-
sion (Fig. 1C). These ﬁndings indicate that TNF- and OPN
expressions were closely related in vivo.
Induction of OPN expression in fatty HepG2 cells.
Because we show a correlation between OPN expression
and steatosis, we wanted to determine if triglyceride
accumulation was sufﬁcient to induce OPN expression in
cultured HepG2 cells. Triglyceride accumulation in HepG2
cells was induced by incubation with oleic acid for 24 h.
Interestingly, this was associated with a marked increase
in the OPN mRNA expression compared with cells cul-
tured in the control medium (Fig. 2).
OPN and CD44 gene expressions in adipose tissue
from morbidly obese patients. We next evaluated OPN
and CD44 expressions in the adipose tissue that could be
obtained in a set of patients without hepatic steatosis and
insulin resistance (S0/IR
, n  9) and in patients with
severe hepatic steatosis and insulin resistance (S3/IR
	,
n  23) compared with adipose tissue obtained in seven
controls subjects. OPN mRNA expression level was signif-
icantly increased in the adipose tissue of morbidly obese
patients (S0 and S3) compared with lean controls, but
different from liver, independently from steatosis and
insulin resistance (Fig. 3A). Although comparing mRNA
expression from liver, subcutaneous adipose tissue
(SCAT) and visceral adipose tissue (VAT) have to be
cautiously taken; OPN mRNA expression was much higher
in adipose tissues than in liver but did not signiﬁcantly
differ in both adipose tissues (VAT vs. liver: 2.96  0.54,
P  0.05, n  16; SCAT vs. liver: 5.02  1.92, P  0.05, n 
16; SCAT vs. VAT: 1.66  0.40, NS, n  16). There was no
difference in CD44 mRNA expression levels in subcutane-
ous adipose tissue between lean controls and morbidly
obese patients (S0 as well as S3) (Fig. 3A). Noteworthy,
the CD44 gene expression was much higher in both
adipose tissues than in liver (VAT vs. liver: 2.48  0.37, P 
0.05, n  16; SCAT vs. liver: 3.20  0.55, P  0.05, n  16).
Because invalidation of OPN prevents macrophages
inﬁltration into mouse adipose tissue (9), we then com-
pared the OPN gene expression in adipose tissue with that
of a macrophages marker, CD68, in 39 patients from the
cohort with a wide range of OPN expression. As shown in
Fig. 3B, the OPN mRNA expression level was strongly and
signiﬁcantly correlated with the macrophage inﬁltration,
as evaluated by CD68 expression. In accordance with this
result, macrophage inﬁltration was increased in subcuta-
neous adipose tissue from obese patients (n  19) versus
lean subjects (n  4) (Fig. 3C) and was correlated with the
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FIG. 2. The OPN expression in human HepG2 cells is enhanced after the
accumulation of triglycerides. HepG2 cells were incubated without (0)
or with 1 mmol/l oleic acid (OA) for 24 h. Intracellular TG levels were
determined and normalized to cell protein content. OPN mRNA expres-
sion was analyzed by real-time quantitative PCR. Data were expressed
as means  SE of three independent experiments. *P < 0.05.
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FIG. 3. The OPN mRNA expression is increased in subcutaneous
adipose tissue of morbidly obese patients and is signiﬁcantly corre-
lated with macrophage accumulation. A: OPN and CD44 mRNA expres-
sion levels were analyzed by real-time quantitative PCR in
subcutaneous adipose tissue of lean patients (controls; n  7), mor-
bidly obese patients without liver steatosis and insulin resistance
(S0/IR
; n  9), and morbidly obese patients with severe steatosis and
insulin resistance (S3/IR
; n  23). Data are presented as relative
mRNA normalized to RPLP0 mRNA and are expressed as means  SE.
*P < 0.05. B: Correlation between OPN and CD68 mRNA expression
levels (Ct) was analyzed using Spearman’s rank correlation test. C:
The percentage of macrophages in subcutaneous adipose tissue has
been evaluated in lean subjects (controls; n  4), S0/IR
 obese
patients (n  4), and S3/IR
 obese patients (n  11).
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not shown).
Effect of weight loss on adipose gene expression. We
then determined if weight loss could modify the gene
expression of OPN, CD44, TNF-, and the macrophage
marker CD68 in abdominal subcutaneous adipose tissue.
Six patients were reevaluated 2 years after their bariatric
surgery. As expected, these patients had a marked weight
loss (44.3  11.4 kg), leading to a notable improvement
of systemic inﬂammation, as evaluated by the circulating
levels of CRP and the insulin resistance as evaluated by
the HOMA-IR (Fig. 4A). Interestingly, in their adipose
tissue, the expression of both OPN and CD44 was drasti-
cally decreased and was associated with an important
decrease in the macrophage inﬁltration, as evaluated by
the CD68 gene expression (Fig. 4B). Furthermore, the
OPN and CD44 mRNA expressions were signiﬁcantly
correlated with CD68 mRNA expression (rs  0.769, P 
0.003; rs  0.790, P  0.002, respectively). In addition,
while TNF- expression was increased in obese patients
compared with the lean patients (2.69  0.26, P  0.05)
(data not shown), it was markedly decreased after weight
loss (Fig. 4B) and was correlated with OPN mRNA expres-
sion (rs  0.741, P  0.006) (data not shown). These
ﬁndings indicate that OPN and CD44 expressions are
strongly related to macrophage accumulation in adipose
tissue.
Circulating OPN levels in morbidly obese patients.
We then measured OPN serum levels in 52 morbidly obese
patients without (S0, n  6) or with liver steatosis (S1, n 
13; S2, n  9; S3, n  24) and control subjects (n  8). As
shown in Fig. 5A, circulating OPN concentrations were
modestly but signiﬁcantly elevated in morbidly obese
patients compared with control subjects (n  8), in
agreement with Gomez-Ambrosi et al. (19). However, the
circulating OPN levels were not correlated with the grade
of liver steatosis (rs  0.129; P  0.268, n  52) (data not
shown). The relative contribution of liver and adipose
tissue in circulating OPN levels is difﬁcult to estimate. To
determine whether circulating OPN could be of adipose
tissue origin, we determined the OPN levels in the arteri-
alized and adipose tissue venous plasma in ﬁve overweight
patients. As shown in Fig. 5B, while adipose tissue en-
riched the circulating levels of leptin, no signiﬁcant differ-
ence between arterialized and venous adipose tissue
samples was observed for OPN. We then investigated if
weight loss could modify the circulating levels of OPN in
25 patients. In accordance with recent reports (29–31), the
circulating OPN level was 1.8-fold increased 1 year after
bariatric surgery in our patients (Fig. 5C).
OPN and CD44 expressions in obese mice. To corrob-
orate the human ﬁndings and to further explore the
potential role of OPN in liver complications of morbid
obesity, a series of experiments were performed in various
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DIABETES, VOL. 58, JANUARY 2009 129animal models. As expected, mice exposed to HFD exhib-
ited increased weight (45.1  3.2 vs. 28.2  1.6 g in low-fat
diet–fed controls), increased hepatic triglyceride content
(73  14 vs. 37  12 g/mg liver), hyperglycemia (208  90
vs. 100  16 mg/dl), and hyperinsulinemia (2.31  0.63 vs.
0.95  0.89 g/l). HFD-induced obesity resulted in in-
creased OPN and CD44 gene expressions in both fatty liver
and epididymal WAT (Fig. 6A). Interestingly, the hepatic
expressions of OPN and CD44 were also positively corre-
lated with steatosis, as evaluated by hepatic triglyceride
content (Fig. 6B). Similar ﬁndings were observed in ge-
netic leptin-deﬁcient (ob/ob) mice (n  5), since OPN and
CD44 gene expressions were found to be signiﬁcantly
enhanced in both liver (3.3  0.3, P  0.05, and 1.6 
0.1-fold, P  0.05, respectively) and adipose tissue (23.4 
2.5, P  0.05, and 5.2  0.8-fold, P  0.05, respectively)
compared with lean littermates (n  5). In addition, the
adipose tissue expressions of OPN and CD44 were corre-
lated with expression of the macrophage marker F4/80 in
HFD-induced obese mice (rs  0.820, P  0.01, and rs 
0.843, P  0.01, respectively). Furthermore, serum OPN
levels were also signiﬁcantly increased, but this increase
was moderate, as occurred in liver and adipose tissue
(Fig. 6C).
We then investigated which liver cell population could
be responsible for OPN and CD44 expression. Cells from
livers of ob/	 mice were separated into hepatocytes and
nonparenchymal fractions. As shown in Fig. 6D, real-time
PCR analysis revealed that OPN expression was seven
times higher in hepatocytes than in the nonparenchymal
fraction. In contrast, CD44 was predominantly expressed
in the nonparenchymal fraction. To secure the quality of
the separation procedure, albumin and CD11b expression
was used as markers of hepatocyte and inﬂammatory
cells, respectively. Albumin was predominantly expressed
in the hepatocyte fraction (45  11, P  0.05) as well as
OPN, whereas CD11b was predominantly expressed in the
nonparenchymal fraction (34  27, P  0.05) (data not
shown) as well as CD44.
DISCUSSION
We report here that the increased expression of OPN in
adipose tissue was associated with the accumulation of
macrophages in the adipose tissue. We also describe for
the ﬁrst time that, in patients with severe steatosis and
insulin resistance, the hepatic OPN gene expression, as
well as the expression of its receptor CD44, were mark-
edly increased and related to the severity of hepatic
steatosis. This progressive upregulation of the hepatic
OPN gene was signiﬁcantly associated with liver injury (as
evaluated by plasma ALT levels) and hepatic insulin
resistance (as evaluated by the HOMA-IR). Local concen-
trations of OPN in liver and adipose tissue do not appear
to affect its systemic levels. Indeed, the modest elevation
of systemic OPN in obese patients is not related to liver
steatosis or to its marked increase in adipose tissue.
Furthermore, weight loss after bariatric surgery was in-
deed associated with a strong decrease in OPN expression
in the adipose tissue, whereas an opposite increase was
observed in its systemic level.
OPN plays an important role in inﬁltration and accumu-
lation of macrophages in adipose tissue in the early stages
of obesity. In vitro chemotaxis assays have revealed that
OPN ampliﬁed macrophage migration (9). In addition,
endogenous OPN in macrophage is required to maintain
macrophage function including chemotaxis, an effect
mediated by the interaction with its receptor CD44
(9,17,32,33). The increase in the production of such a
pro-inﬂammatory adipokine could activate macrophages
already present in the stromal vascular fraction of adipose
tissue resulting in an increased production of migratory
signal including OPN itself. This could contribute to the
over-enrichment of adipose tissue in macrophages. How-
ever, the recruitment into adipose tissue of macrophages
derived from the circulation in the early stage of obesity is
a complex mechanism (5). Other chemokines may play an
important role, such as monocyte chemoattractant pro-
tein-1 (MCP-1) (produced primarily by adipocytes) with
elevated plasma levels in obese patients (34). Indeed,
MCP-1 exerts additive effects on chemotaxis in the pres-
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130 DIABETES, VOL. 58, JANUARY 2009ence of OPN and ampliﬁes macrophage migration to the
same extent than OPN (9).
It has been proposed that the accumulation of macro-
phages in adipose tissue mediated by OPN, per se, as well
as by MCP-1, resulting in an increased macrophage-related
inﬂammatory activity, could be a link between inﬂamma-
tion and insulin resistance (9,35–37). Indeed, the respec-
tive invalidation of OPN, MCP-1, or its receptor CCR2
prevents the macrophage accumulation in adipose tissue,
inﬂammation, and insulin resistance mediated by HFD-
induced obesity (9,35–37). This appealing hypothesis was
further supported by our studies conﬁrming a marked
increase in OPN as well as CD44 gene expressions in both
liver and adipose tissue in two murine models of obesity.
Of particular interest, in the HFD model, OPN and CD44
gene expressions were well correlated with the accumu-
lation of macrophages in adipose tissue.
Because there is a direct link between OPN-induced
macrophage accumulation and insulin resistance, the ben-
eﬁcial effect of weight loss or treatment with anti-inﬂam-
matory drugs (PPAR agonists) on inﬂammation and
glucose homeostasis should be associated with a decrease
in OPN expression. Indeed, we have shown that weight
loss after bariatric surgery resulted in a strong reduction in
OPN expression in adipose tissue, together with the
marked diminution in the accumulation of macrophages
also reported in previous studies (38,39). In these patients,
weight loss was also associated with a decreased periph-
eral inﬂammation (as evaluated by plasma CRP levels) and
an improvement in insulin sensitivity. On the other hand,
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rophages (21,22) and decrease plasma levels in treated
patients (21).
However, the role of circulating OPN in the macrophage
inﬁltration into adipose tissue has not yet been estab-
lished. We show here that in obese patients and mice, OPN
expression was modestly elevated in serum but markedly
increased in adipose tissue compared with lean subjects or
mice. Whereas weight loss after bariatric surgery resulted
in a strong reduction in OPN and CD44 expression and
macrophage accumulation in adipose tissue, the circulat-
ing levels of OPN were enhanced. In accordance with this
result, recent reports have shown that elevated OPN
plasma concentration 1 year after bariatric surgery was
correlated with markers of bone turnover but not with
insulin resistance and inﬂammation (29,30). On the con-
trary, diet-induced weight loss could decrease circulating
OPN levels (19). Local concentrations of OPN might be
different from systemic levels. Furthermore, the tissues or
organs contributing to the modestly elevated circulating
OPN levels in obese patients were very difﬁcult to esti-
mate. Whereas we show for the ﬁrst time that systemic
OPN levels were not correlated with the grade of liver
steatosis and that adipose tissue from overweight patients
did not appear to secrete OPN, additional studies are
required to know the organ origin of the circulating OPN.
It is currently accepted that insulin resistance can
contribute to the development of hepatic steatosis (35,36)
through the increased release of free fatty acids secondary
to unsuppressed lipolysis (6,8). In addition, the combined
elevation of plasma glucose and insulin levels promotes de
novo lipid synthesis and impairs lipid oxidation within
hepatocytes, further promoting the excessive fatty acids
accumulation (6–8). The present data clearly show that in
obese patients and mice, the expression of OPN in adipose
tissue was positively correlated with macrophage mark-
ers. In addition, the hepatic OPN and CD44 gene expres-
sions were signiﬁcantly increased in the presence of
severe steatosis, and this increase was correlated with the
severity of steatosis. In parallel, the hepatic OPN protein
itself was strongly elevated in obese patients with severe
steatosis. Although direct cause-effect relationships can-
not be inferred from our data, modiﬁcation of all parame-
ters could be linked to the severity of steatosis. While the
role of OPN in the development of liver complications has
not been fully elucidated, invalidation of the OPN gene
reduces the plasma ALAT elevation as well as the hepatic
inﬂammation and ﬁbrosis in mice fed a choline-methio-
nine–deﬁcient diet (10).
The cellular origin of the increased hepatic OPN expres-
sion has not been yet determined. Although an increased
hepatic OPN gene expression has been reported in mac-
rophages, Ku ¨pffer cells, and stellate cells in response to
carbon tetrachloride (40), we show here that hepatocytes
versus the nonhepatocyte cells are the main source of
OPN in normal mouse liver. Most interestingly, our in vitro
steatosis studies clearly demonstrate that human HepG2
cells cultured in the presence of fatty acids rapidly accu-
mulate triglycerides and, concomitantly, the OPN gene
expression is rapidly induced.
In summary, we have shown that OPN expression was
increased in the adipose tissue early in the course of
obesity-induced insulin resistance and before the occur-
rence of liver steatosis. In morbidly obese patients, OPN
could enhance macrophage inﬁltration and accumulation
in the adipose tissue, thus contributing to inﬂammation
and insulin resistance. In the presence of insulin resis-
tance, the accumulation of triglycerides in liver was then
associated with an additional upregulation of hepatic OPN
and CD44 expression, well related to the severity of
steatosis. In addition the hepatic gene expressions of OPN
and of its receptor, CD44, were related to the liver injury
and hepatic insulin resistance. Our original ﬁndings con-
cerning the effects of triglyceride accumulation on hepa-
toma cells on OPN expression offer some interesting
mechanistic explanations for the role of OPN in the
development of NAFLD in humans and rodent models.
Studies focusing on the behavior of hepatic OPN and CD44
signaling in the progression from normal liver toward
steatosis, steatohepatitis, and ﬁbrosis are attractive ap-
proaches to acquire more insight into the pathogenesis of
human NAFLD.
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